ECT204 T-Cell Therapy for Liver Cancer
(ARYA-3 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called ECT204 T-cell therapy for liver cancer, specifically targeting GPC3-positive HCC. Researchers aim to assess the safety of this treatment and its potential to combat cancer when other treatments have failed. The trial consists of two parts: determining the optimal dose and then testing its effectiveness. Suitable candidates are adults with inoperable liver cancer, specific tumor markers, and a history of unsuccessful treatment with at least two other cancer therapies. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.
Do I need to stop my current medications for the ECT204 T-Cell Therapy trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on other investigational agents or liver tumor-directed therapies while participating.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that ECT204 T-cell therapy is still under investigation, but some findings about its safety have emerged. T-cell therapy uses a person's own modified immune cells to combat cancer, and this treatment has shown promise in targeting liver cancer cells.
In earlier studies, some patients experienced partial remissions, where their cancer reduced in size, while others maintained stable disease for over three years, meaning their cancer did not progress. This suggests the treatment can be effective without severe side effects for some individuals.
However, this remains an investigational treatment in the middle stages of testing, requiring further research to fully understand its safety. Participants in the study are closely monitored for any side effects, and researchers adjust doses to determine the safest amount.
For those considering joining this trial, it is important to remember that the treatment is experimental, but there is growing evidence that it can be well-tolerated by some patients. Always discuss any concerns or questions with a doctor to understand the possible risks and benefits.12345Why are researchers excited about this trial's treatments?
Researchers are excited about ECT204 T-cell therapy for liver cancer because it harnesses the power of modified T cells to specifically target and attack cancer cells. Unlike traditional treatments like surgery, chemotherapy, and targeted therapies such as sorafenib, which can affect both healthy and cancerous tissues, ECT204 offers a precision approach with the potential for fewer side effects. Additionally, in one treatment arm, regorafenib is used as a pre-treatment to potentially enhance the T-cell therapy's effectiveness, offering a novel combination strategy that could improve outcomes for patients.
What evidence suggests that this trial's treatments could be effective for liver cancer?
Studies have shown that ECT204 T-cell therapy targets a protein called GPC3, often found in large amounts on liver cancer cells, particularly in hepatocellular carcinoma (HCC). Research indicates that these specially designed T-cells can effectively identify and attack these cancer cells. In early studies, ECT204 demonstrated strong activity against tumors with GPC3. Initial findings suggest that this therapy could help shrink tumors or slow their growth in patients with advanced liver cancer.
In this trial, participants will join different treatment arms. One arm will receive ECT204 T-cell therapy as monotherapy, while another will receive ECT204 T-cell therapy following pre-treatment with regorafenib. This approach represents a promising new way to treat liver cancer by harnessing the body's immune system.12346Who Is on the Research Team?
Pei Wang, PhD
Principal Investigator
Eureka Therapeutics Inc.
Are You a Good Fit for This Trial?
Adults with advanced liver cancer (HCC) who have tried at least two treatments without success can join this trial. They should have a life expectancy of 4+ months, good organ function, and their cancer must show GPC3-positive expression. A score indicating mild liver disease (Child-Pugh A6 or better) and a performance status showing they're mostly independent are also required.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 (Dose Escalation)
Completed; RP2D of ECT204 was determined
Phase 2 (Expansion)
Subjects receive ECT204 as monotherapy or with pre-treatment regorafenib
Long Term Follow-Up
Subjects are followed for assessment of treatment safety and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- ECT204 T cells
ECT204 T cells is already approved in United States for the following indications:
- Hepatocellular carcinoma (HCC) - Orphan drug designation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eureka Therapeutics Inc.
Lead Sponsor